Skip to content

Title 42 — The Public Health and Welfare

Part A · Chapter 6A — Public Health Service

§ 283g. Muscular dystrophy; initiative through Director of National Institutes of Health

Statutory text

(a)

Expansion, intensification, and coordination of activities

(1)

In general

The Director of NIH, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Heart, Lung, and Blood Institute, and the other national research institutes as appropriate, shall expand and intensify programs of such Institutes with respect to research and related activities concerning various forms of muscular dystrophy, including Duchenne, Becker, congenital muscular dystrophy, limb-girdle muscular dystrophy, myotonic, facioscapulohumeral muscular dystrophy (referred to in this section as “FSHD”) and other forms of muscular dystrophy.

(2)

Coordination

The Directors referred to in paragraph (1) shall jointly coordinate the programs referred to in such paragraph and consult with the Muscular Dystrophy Interagency Coordinating Committee established under section 6 of the MD–CARE Act.1

(3)

Allocations by Director of NIH

The Director of NIH shall allocate the amounts appropriated to carry out this section for each fiscal year among the national research institutes referred to in paragraph (1).

(b)

Centers of excellence

(1)

In general

The Director of NIH shall award grants and contracts under subsection (a)(1) to public or nonprofit private entities to pay all or part of the cost of planning, establishing, improving, and providing basic operating support for centers of excellence regarding research on various forms of muscular dystrophy. Such centers of excellence shall be known as the “Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers”.

(2)

Research

Each center under paragraph (1) shall supplement but not replace the establishment of a comprehensive research portfolio in all the muscular dystrophies. As a whole, the centers shall conduct basic and clinical research in all forms of muscular dystrophy including early detection, diagnosis, prevention, and treatment, including the fields of muscle biology, genetics, noninvasive imaging, cardiac and pulmonary function, and pharmacological and other therapies.

(3)

Coordination of centers

The Director of NIH shall, as appropriate, provide for the coordination of information among centers under paragraph (1) and ensure regular communication and sharing of data between such centers.

(4)

Organization of centers

Each center under paragraph (1) shall use the facilities of a single institution, or be formed from a consortium of cooperating institutions, meeting such requirements as may be prescribed by the Director of NIH.

(5)

Duration of support

Support for a center established under paragraph (1) may be provided under this section for a period of not to exceed 5 years. Such period may be extended for 1 or more additional periods not exceeding 5 years if the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director of NIH and if such group has recommended to the Director that such period should be extended.

(c)

Facilitation of research

The Director of NIH shall provide for a program under subsection (a)(1) under which samples of tissues and genetic materials that are of use in research on muscular dystrophy are donated, collected, preserved, and made available for such research. The program shall be carried out in accordance with accepted scientific and medical standards for the donation, collection, and preservation of such samples.

(d)

Coordinating Committee

(1)

In general

The Secretary shall establish the Muscular Dystrophy Coordinating Committee (referred to in this section as the “Coordinating Committee”) to coordinate activities across the National Institutes and with other Federal health programs and activities relating to the various forms of muscular dystrophy.

(2)

Composition

The Coordinating Committee shall consist of not more than 18 members to be appointed by the Secretary, of which—

(A)

⅔ of such members shall represent governmental agencies, including the directors or their designees of each of the national research institutes involved in research with respect to muscular dystrophy and representatives of all other Federal departments and agencies whose programs involve health functions or responsibilities relevant to such diseases, including the Centers for Disease Control and Prevention, the Health Resources and Services Administration, the Food and Drug Administration, and the Administration for Community Living and representatives of other governmental agencies that serve children and adults with muscular dystrophy, including the Department of Education and the Social Security Administration; and

(B)

⅓ of such members shall be public members, including a broad cross section of persons affected with muscular dystrophies including parents or legal guardians, affected individuals, researchers, and clinicians.

Members appointed under subparagraph (B) shall serve for a term of 3 years, and may serve for an unlimited number of terms if reappointed.

(3)

Chair

(A)

In general

With respect to muscular dystrophy, the Chair of the Coordinating Committee shall serve as the principal advisor to the Secretary, the Assistant Secretary for Health, and the Director of NIH, and shall provide advice to the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, and to the heads of other relevant agencies. The Coordinating Committee shall select the Chair for a term not to exceed 2 years.

(B)

Appointment

The Chair of the Committee shall be appointed by and be directly responsible to the Secretary.

(4)

Administrative support; terms of service; other provisions

The following shall apply with respect to the Coordinating Committee:

(A)

The Coordinating Committee shall receive necessary and appropriate administrative support from the Department of Health and Human Services.

(B)

The Coordinating Committee shall meet as appropriate as determined by the Secretary, in consultation with the chair,2 but shall meet no fewer than two times per calendar year.

(e)

Plan for HHS activities

(1)

In general

Not later than 1 year after , the Coordinating Committee shall develop a plan for conducting and supporting research and education on muscular dystrophy through the agencies represented on the Coordinating Committee pursuant to subsection (d)(2)(A) and shall periodically review and revise the plan. The plan shall—

(A)

provide for a broad range of research and education activities relating to biomedical, epidemiological, psychosocial, public services, and rehabilitative issues, including studies of the impact of such diseases in rural and underserved communities, studies to demonstrate the cost-effectiveness of providing independent living resources and support to patients with various forms of muscular dystrophy, and studies to determine optimal clinical care interventions for adults with various forms of muscular dystrophy;

(B)

identify priorities among the programs and activities of the National Institutes of Health regarding such diseases; and

(C)

reflect input from a broad range of scientists, patients, and advocacy groups.

(2)

Certain elements of plan

The plan under paragraph (1) shall, with respect to each form of muscular dystrophy, provide for the following as appropriate:

(A)

Research to determine the reasons underlying the incidence and prevalence of various forms of muscular dystrophy.

(B)

Basic research concerning the etiology and genetic links of the disease and potential causes of mutations.

(C)

The development of improved screening techniques.

(D)

Basic and clinical research for the development and evaluation of new treatments, including new biological agents and new clinical interventions to improve the health of those with muscular dystrophy.

(E)

Information and education programs for health care professionals and the public.

(f)

Public input

The Secretary shall, under subsection (a)(1), provide for a means through which the public can obtain information on the existing and planned programs and activities of the Department of Health and Human Services with respect to various forms of muscular dystrophy and through which the Secretary can receive comments from the public regarding such programs and activities.

(g)

Clinical research

The Coordinating Committee may evaluate the potential need to enhance the clinical research infrastructure required to test emerging therapies for the various forms of muscular dystrophy by prioritizing the achievement of the goals related to this topic in the plan under subsection (e)(1).

Footnotes

  1. 1 See References in Text note below.
  2. 2 So in original. Probably should be capitalized.

Legislative history

Reconstructed from this section’s Code source credit and amendment notes, resolved against the local Statutes at Large. Editorial notes are evidence, not the law that made the change.

  1. Pub. L. 107–84 § 3 · 115 Stat. 823

    Enacted · 42 U.S.C. § 283g

    July 1, 1944, ch. 373, title IV, § 404E, as added Pub. L. 107–84, § 3, Dec. 18, 2001, 115 Stat. 824

    Source evidence

    Code source credit
    July 1, 1944, ch. 373, title IV, § 404E, as added Pub. L. 107–84, § 3, Dec. 18, 2001, 115 Stat. 824

    Enacted provision · exact public law section
    SEC. 3. EXPANSION, INTENSIFICATION, AND COORDINATION OF ACTIVITIES OF NATIONAL INSTITUTES OF HEALTH WITH RESPECT TO RESEARCH ON MUSCULAR DYSTROPHY. Part A of title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) is amended by adding at the end the following: “SEC. 404E. MUSCULAR DYSTROPHY; INITIATIVE THROUGH DIRECTOR OF NATIONAL INSTITUTES OF HEALTH. “(a) Expansion, Intensification, and Coordination of Activities.— “(1) In general.— The Director of NIH, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke, the National Institute of Arthritis and Muscoskeletal and Skin Diseases, the National Institute of Child Health and Human Development, and the other national research institutes as appropriate, shall expand and intensify programs of such Institutes with respect to research and related activities concerning various forms of muscular dystrophy, including Duchenne, myotonic, facioscapulohumeral muscular dystrophy (referred to in this section as ‘FSHD’) and other forms of muscular dystrophy. “(2) Coordination.— The Directors referred to in paragraph (1) shall jointly coordinate the programs referred to in such paragraph and consult with the Muscular Dystrophy Interagency Coordinating Committee established under section 6 of the MD-CARE Act. “(3) Allocations by director of nih.— The Director of NIH shall allocate the amounts appropriated to carry out this section for each fiscal year among the national research institutes referred to in paragraph (1). “(b) Centers of Excellence.— “(1) In general.— The Director of NIH shall award grants Grants. Contracts. and contracts under subsection (a)(1) to public or nonprofit private entities to pay all or part of the cost of planning, establishing, improving, and providing basic operating support for centers of excellence regarding research on various forms of muscular dystrophy. “(2) Research.— Each center under paragraph (1) shall supplement but not replace the establishment of a comprehensive research portfolio in all the muscular dystrophies. As a whole, the centers shall conduct basic and clinical research in all forms of muscular dystrophy including early detection, diagnosis, prevention, and treatment, including the fields of muscle biology, genetics, noninvasive imaging, genetics, pharmacological and other therapies. “(3) Coordination of centers; reports.— The Director of NIH— “(A) shall, as appropriate, provide for the coordination of information among centers under paragraph (1) and ensure regular communication between such centers; and “(B) shall require the periodic preparation of reports on the activities of the centers and the submission of the reports to the Director. “(4) Organization of centers.— Each center under paragraph (1) shall use the facilities of a single institution, or be formed from a consortium of cooperating institutions, meeting such requirements as may be prescribed by the Director of NIH. “(5) Duration of support.— Support for a center established under paragraph (1) may be provided under this section for a period of not to exceed 5 years. Such period may be extended for 1 or more additional periods not exceeding 5 years if the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director of NIH and if such group has recommended to the Director that such period should be extended. “(c) Facilitation of Research.— The Director of NIH shall provide for a program under subsection (a)(1) under which samples of tissues and genetic materials that are of use in research on muscular dystrophy are donated, collected, preserved, and made available for such research. The program shall be carried out in accordance with accepted scientific and medical standards for the donation, collection, and preservation of such samples. “(d) Coordinating Committee.— “(1) In general.— The Secretary shall establish the Muscular Dystrophy Coordinating Committee (referred to in this section as the ‘Coordinating Committee’) to coordinate activities across the National Institutes and with other Federal health programs and activities relating to the various forms of muscular dystrophy. “(2) Composition.— The Coordinating Committee shall consist of not more than 15 members to be appointed by the Secretary, of which— “(A) ⅔ of such members shall represent governmental agencies, including the directors or their designees of each of the national research institutes involved in research with respect to muscular dystrophy and representatives of all other Federal departments and agencies whose programs involve health functions or responsibilities relevant to such diseases, including the Centers for Disease Control and Prevention, the Health Resources and Services Administration and the Food and Drug Administration and representatives of other governmental agencies that serve children with muscular dystrophy, such as the Department of Education; and “(B) ⅓ of such members shall be public members, including a broad cross section of persons affected with muscular dystrophies including parents or legal guardians, affected individuals, researchers, and clinicians. Members appointed under subparagraph (B) shall serve for a term of 3 years, and may serve for an unlimited number of terms if reappointed. “(3) Chair.— “(A) In general.— With respect to muscular dystrophy, the Chair of the Coordinating Committee shall serve as the principal advisor to the Secretary, the Assistant Secretary for Health, and the Director of NIH, and shall provide advice to the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, and to the heads of other relevant agencies. The Coordinating Committee shall select the Chair for a term not to exceed 2 years. “(B) Appointment.— The Chair of the Committee shall be appointed by and be directly responsible to the Secretary. “(4) Administrative support; terms of service; other provisions.— The following shall apply with respect to the Coordinating Committee: “(A) The Coordinating Committee shall receive necessary and appropriate administrative support from the Department of Health and Human Services. “(B) The Coordinating Committee shall meet as appropriate as determined by the Secretary, in consultation with the chair. “(e) Plan for HHS Activities.— “(1) In general.— Not later than 1 year after the date of enactment of this section, the Coordinating Committee shall develop a plan for conducting and supporting research and education on muscular dystrophy through the national research institutes and shall periodically review and revise the plan. The plan shall— “(A) provide for a broad range of research and education activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues, including studies of the impact of such diseases in rural and underserved communities; “(B) identify priorities among the programs and activities of the National Institutes of Health regarding such diseases; and “(C) reflect input from a broad range of scientists, patients, and advocacy groups. “(2) Certain elements of plan.— The plan under paragraph (1) shall, with respect to each form of muscular dystrophy, provide for the following as appropriate: “(A) Research to determine the reasons underlying the incidence and prevalence of various forms of muscular dystrophy. “(B) Basic research concerning the etiology and genetic links of the disease and potential causes of mutations. “(C) The development of improved screening techniques. “(D) Basic and clinical research for the development and evaluation of new treatments, including new biological agents. “(E) Information and education programs for health care professionals and the public. “(f) Reports to Congress.— The Coordinating Committee shall biennially submit to the Committee on Energy and Commerce of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions of the Senate, a report that describes the research, education, and other activities on muscular dystrophy being conducted or supported through the Department of Health and Human Services. Each such report shall include the following: “(1) The plan under subsection (e)(1) (or revisions to the plan, as the case may be). “(2) Provisions specifying the amounts expended by the Department of Health and Human Services with respect to various forms of muscular dystrophy, including Duchenne, myotonic, FSHD and other forms of muscular dystrophy. “(3) Provisions identifying particular projects or types of projects that should in the future be considered by the national research institutes or other entities in the field of research on all muscular dystrophies. “(g) Public Input.— The Secretary shall, under subsection (a)(1), provide for a means through which the public can obtain information on the existing and planned programs and activities of the Department of Health and Human Services with respect to various forms of muscular dystrophy and through which the Secretary can receive comments from the public regarding such programs and activities. “(h) Authorization of Appropriations.— For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2002 through 2006. The authorization of appropriations established in the preceding sentence is in addition to any other authorization of appropriations that is available for conducting or supporting through the National Institutes of Health research and other activities with respect to muscular dystrophy.”.

  2. National Institutes of Health Reform Act of 2006

    Pub. L. 109–482 § 104(b)(1)(A)(ii) · 120 Stat. 3675

    1. Struck · 42 U.S.C. § 283g

      Pub. L. 109–482, § 104(b)(1)(A)(ii), which directed amendment of subsec. (b) by striking subsec. (f)

    2. Redesignated · 42 U.S.C. § 283g

      Pub. L. 109–482, § 104(b)(1)(A)(ii), which directed amendment of subsec. (b) by redesignating subsec. (g) as (f), could not literally be executed and was not executed in view of amendments by Pub. L. 110–361. See 2008 Amendment notes above

    Source evidence

    Code amendment note
    Pub. L. 109–482, § 104(b)(1)(A)(ii), which directed amendment of subsec. (b) by striking subsec. (f) and redesignating subsec. (g) as (f), could not literally be executed and was not executed in view of amendments by Pub. L. 110–361. See 2008 Amendment notes above.

    Enacted provision · exact public law section
    (ii) by striking subsection (f) and redesignating subsection (g) as subsection (f);

    Effective date note
    Amendment by Pub. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109–482, set out as a note under section 281 of this title.

  3. National Institutes of Health Reform Act of 2006

    Pub. L. 109–482 § 104(b)(1)(A)(i) · 120 Stat. 3675

    Amended · 42 U.S.C. § 283g(b)(3)

    Pub. L. 109–482, § 104(b)(1)(A)(i), amended heading and text of par. (3) generally. Text read as follows: “The Director of NIH—

    Source evidence

    Code amendment note
    Subsec. (b)(3). Pub. L. 109–482, § 104(b)(1)(A)(i), amended heading and text of par. (3) generally. Text read as follows: “The Director of NIH—

    “(A) shall, as appropriate, provide for the coordination of information among centers under paragraph (1) and ensure regular communication between such centers; and “(B) shall require the periodic preparation of reports on the activities of the centers and the submission of the reports to the Director.”

    Enacted provision · exact public law section
    (i) by amending paragraph (3) to read as follows: “(3) Coordination of centers.— The Director of NIH shall, as appropriate, provide for the coordination of information among centers under paragraph (1) and ensure regular communication between such centers.” ; and

    Effective date note
    Amendment by Pub. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109–482, set out as a note under section 281 of this title.

  4. National Institutes of Health Reform Act of 2006

    Pub. L. 109–482 § 103(b)(4) · 120 Stat. 3675

    Struck · 42 U.S.C. § 283g(h)

    Pub. L. 109–482, § 103(b)(4), struck out heading and text of subsec. (h). Text read as follows: “For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2002 through 2006. The authorization of appropriations established in the preceding sentence is in addition to any other authorization of appropriations that is available for conducting or supporting through the National Institutes of Health research and other activities with respect to muscular dystrophy.”

    Source evidence

    Code amendment note
    Subsec. (h). Pub. L. 109–482, § 103(b)(4), struck out heading and text of subsec. (h). Text read as follows: “For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2002 through 2006. The authorization of appropriations established in the preceding sentence is in addition to any other authorization of appropriations that is available for conducting or supporting through the National Institutes of Health research and other activities with respect to muscular dystrophy.”

    Enacted provision · exact public law section
    (4) by striking subsection (h) of section 42 USC 283g. 404E;

    Effective date note
    Amendment by Pub. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109–482, set out as a note under section 281 of this title.

  5. Pub. L. 110–154 § 1(b)(3) · 121 Stat. 1826

    Substituted · 42 U.S.C. § 283g(a)(1)

    Pub. L. 110–154 substituted “Eunice Kennedy Shriver National Institute of Child Health and Human Development” for “National Institute of Child Health and Human Development”

    Source evidence

    Code amendment note
    Subsec. (a)(1). Pub. L. 110–154 substituted “Eunice Kennedy Shriver National Institute of Child Health and Human Development” for “National Institute of Child Health and Human Development”.

    Enacted provision · exact public law section
    (3) in section 404E(a) (42 U.S.C. 283g(a)), by striking “National Institute of Child Health and Human Development” and inserting “Eunice Kennedy Shriver National Institute of Child Health and Human Development”;

  6. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008

    Pub. L. 110–361 § 2(b)(1) · 122 Stat. 4010

    Inserted · 42 U.S.C. § 283g(a)(1)

    Pub. L. 110–361, § 2(b)(1), inserted “the National Heart, Lung, and Blood Institute,” after “the Eunice Kennedy Shriver National Institute of Child Health and Human Development,”

    Source evidence

    Code amendment note
    Subsec. (a)(1). Pub. L. 110–361, § 2(b)(1), inserted “the National Heart, Lung, and Blood Institute,” after “the Eunice Kennedy Shriver National Institute of Child Health and Human Development,”.

    Enacted provision · exact public law section
    (1) in subsection (a)(1), by inserting “the National Heart, Lung, and Blood Institute,” after “the Eunice Kennedy Shriver National Institute of Child Health and Human Development,”;

  7. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008

    Pub. L. 110–361 § 2(b)(2) · 122 Stat. 4010

    Inserted · 42 U.S.C. § 283g(b)(1)

    Pub. L. 110–361, § 2(b)(2), inserted at end “Such centers of excellence shall be known as the ‘Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers’.”

    Source evidence

    Code amendment note
    Subsec. (b)(1). Pub. L. 110–361, § 2(b)(2), inserted at end “Such centers of excellence shall be known as the ‘Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers’.”

    Enacted provision · exact public law section
    (2) Federal buildings and facilities. in subsection (b)(1), by adding at the end of the following: “Such centers of excellence shall be known as the ‘Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers’.”; and

  8. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008

    Pub. L. 110–361 § 2(a) · 122 Stat. 4010

    1. Redesignated · 42 U.S.C. § 283g(f)

      Pub. L. 110–361, § 2(a), redesignated subsec. (g) as (f)

    2. Struck · 42 U.S.C. § 283g(f)

      Pub. L. 110–361, § 2(a), struck out former subsec. (f) which related to reports

    Source evidence

    Code amendment note
    Subsec. (f). Pub. L. 110–361, § 2(a), redesignated subsec. (g) as (f) and struck out former subsec. (f) which related to reports.

    Enacted provision · exact public law section
    (a) Technical Correction.— Section 404E of the Public Health Service Act (42 U.S.C. 283g) is amended by striking subsection (f) (relating to reports to Congress) and redesignating subsection (g) as subsection (f).

  9. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008

    Pub. L. 110–361 § 2(a) · 122 Stat. 4010

    1. Added · 42 U.S.C. § 283g(g)

      Pub. L. 110–361, § 2(a), (b)(3), added subsec. (g)

    2. Redesignated · 42 U.S.C. § 283g(g)

      Pub. L. 110–361, § 2(a), (b)(3), redesignated former subsec. (g) as (f)

    Source evidence

    Code amendment note
    Subsec. (g). Pub. L. 110–361, § 2(a), (b)(3), added subsec. (g) and redesignated former subsec. (g) as (f).

    Enacted provision · exact public law section
    (a) Technical Correction.— Section 404E of the Public Health Service Act (42 U.S.C. 283g) is amended by striking subsection (f) (relating to reports to Congress) and redesignating subsection (g) as subsection (f).

  10. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(1) · 128 Stat. 1879

    1. Substituted · 42 U.S.C. § 283g(a)(1)

      Pub. L. 113–166, § 2(1), substituted “Musculoskeletal” for “Muscoskeletal”

    2. Inserted · 42 U.S.C. § 283g(a)(1)

      Pub. L. 113–166, § 2(1), inserted “Becker, congenital muscular dystrophy, limb-girdle muscular dystrophy,” after “Duchenne,”

    Source evidence

    Code amendment note
    Subsec. (a)(1). Pub. L. 113–166, § 2(1), substituted “Musculoskeletal” for “Muscoskeletal” and inserted “Becker, congenital muscular dystrophy, limb-girdle muscular dystrophy,” after “Duchenne,”.

    Enacted provision · exact public law section
    (1) in subsection (a)(1)— (A) by striking “Muscoskeletal” and inserting “Musculoskeletal”; and (B) by inserting “Becker, congenital muscular dystrophy, limb-girdle muscular dystrophy,” after “Duchenne,”;

  11. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(2)(A) · 128 Stat. 1879

    Substituted · 42 U.S.C. § 283g(b)(2)

    Pub. L. 113–166, § 2(2)(A), substituted “cardiac and pulmonary function, and pharmacological” for “genetics, pharmacological”

    Source evidence

    Code amendment note
    Subsec. (b)(2). Pub. L. 113–166, § 2(2)(A), substituted “cardiac and pulmonary function, and pharmacological” for “genetics, pharmacological”.

    Enacted provision · exact public law section
    (A) in paragraph (2)— (i) by striking “genetics,” at the second place it appears; and (ii) by inserting “cardiac and pulmonary function, and” after “imaging,”; and

  12. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(2)(B) · 128 Stat. 1879

    Inserted · 42 U.S.C. § 283g(b)(3)

    Pub. L. 113–166, § 2(2)(B), inserted “and sharing of data” after “regular communication”

    Source evidence

    Code amendment note
    Subsec. (b)(3). Pub. L. 113–166, § 2(2)(B), inserted “and sharing of data” after “regular communication”.

    Enacted provision · exact public law section
    (B) in paragraph (3), by inserting “and sharing of data” after “regular communication”;

  13. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(3)(A)(i) · 128 Stat. 1879

    Substituted · 42 U.S.C. § 283g(d)(2)

    Pub. L. 113–166, § 2(3)(A)(i), substituted “18” for “15” in introductory provisions

    Source evidence

    Code amendment note
    Subsec. (d)(2). Pub. L. 113–166, § 2(3)(A)(i), substituted “18” for “15” in introductory provisions.

    Enacted provision · exact public law section
    (i) in the matter preceding subparagraph (A), by striking “15” and inserting “18”; and

  14. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(3)(A)(ii) · 128 Stat. 1879

    1. Substituted · 42 U.S.C. § 283g(d)(2)(A)

      Pub. L. 113–166, § 2(3)(A)(ii), substituted “, the Food and Drug Administration, and the Administration for Community Living” for “and the Food and Drug Administration”

    2. Substituted · 42 U.S.C. § 283g(d)(2)(A)

      Pub. L. 113–166, § 2(3)(A)(ii), substituted “including the Department of Education and the Social Security Administration” for “such as the Department of Education”

    3. Inserted · 42 U.S.C. § 283g(d)(2)(A)

      Pub. L. 113–166, § 2(3)(A)(ii), inserted “and adults” after “children”

    Source evidence

    Code amendment note
    Subsec. (d)(2)(A). Pub. L. 113–166, § 2(3)(A)(ii), substituted “, the Food and Drug Administration, and the Administration for Community Living” for “and the Food and Drug Administration” and “including the Department of Education and the Social Security Administration” for “such as the Department of Education” and inserted “and adults” after “children”.

    Enacted provision · exact public law section
    (ii) in subparagraph (A)— (I) by striking “and the Food and Drug Administration” and inserting “, the Food and Drug Administration, and the Administration for Community Living”; (II) by inserting “and adults” after “children”; and (III) by striking “such as the Department of Education” and inserting “including the Department of Education and the Social Security Administration”; and

  15. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(3)(B) · 128 Stat. 1879

    Inserted · 42 U.S.C. § 283g(d)(4)(B)

    Pub. L. 113–166, § 2(3)(B), inserted “, but shall meet no fewer than two times per calendar year” before period at end

    Source evidence

    Code amendment note
    Subsec. (d)(4)(B). Pub. L. 113–166, § 2(3)(B), inserted “, but shall meet no fewer than two times per calendar year” before period at end.

    Enacted provision · exact public law section
    (B) in paragraph (4)(B), by inserting “, but shall meet no fewer than two times per calendar year” before the period; and

  16. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(4)(A)(i) · 128 Stat. 1879

    Substituted · 42 U.S.C. § 283g(e)(1)

    Pub. L. 113–166, § 2(4)(A)(i), substituted “through the agencies represented on the Coordinating Committee pursuant to subsection (d)(2)(A)” for “through the national research institutes” in introductory provisions

    Source evidence

    Code amendment note
    Subsec. (e)(1). Pub. L. 113–166, § 2(4)(A)(i), substituted “through the agencies represented on the Coordinating Committee pursuant to subsection (d)(2)(A)” for “through the national research institutes” in introductory provisions.

    Enacted provision · exact public law section
    (i) in the matter preceding subparagraph (A), by striking “through the national research institutes” and inserting “through the agencies represented on the Coordinating Committee pursuant to subsection (d)(2)(A)”; and

  17. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(4)(A)(ii) · 128 Stat. 1879

    Inserted · 42 U.S.C. § 283g(e)(1)(A)

    Pub. L. 113–166, § 2(4)(A)(ii), inserted “public services,” after “psychosocial,” and “, studies to demonstrate the cost-effectiveness of providing independent living resources and support to patients with various forms of muscular dystrophy, and studies to determine optimal clinical care interventions for adults with various forms of muscular dystrophy” after “including studies of the impact of such diseases in rural and underserved communities”

    Source evidence

    Code amendment note
    Subsec. (e)(1)(A). Pub. L. 113–166, § 2(4)(A)(ii), inserted “public services,” after “psychosocial,” and “, studies to demonstrate the cost-effectiveness of providing independent living resources and support to patients with various forms of muscular dystrophy, and studies to determine optimal clinical care interventions for adults with various forms of muscular dystrophy” after “including studies of the impact of such diseases in rural and underserved communities”.

    Enacted provision · exact public law section
    (ii) in subparagraph (A)— (I) by inserting “public services,” before “and rehabilitative issues”; and (II) by inserting “, studies to demonstrate the cost-effectiveness of providing independent living resources and support to patients with various forms of muscular dystrophy, and studies to determine optimal clinical care interventions for adults with various forms of muscular dystrophy” after “including studies of the impact of such diseases in rural and underserved communities”; and

  18. Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2014

    Pub. L. 113–166 § 2(4)(B) · 128 Stat. 1879

    Inserted · 42 U.S.C. § 283g(e)(2)(D)

    Pub. L. 113–166, § 2(4)(B), inserted “and new clinical interventions to improve the health of those with muscular dystrophy” after “including new biological agents”

    Source evidence

    Code amendment note
    Subsec. (e)(2)(D). Pub. L. 113–166, § 2(4)(B), inserted “and new clinical interventions to improve the health of those with muscular dystrophy” after “including new biological agents”.

    Enacted provision · exact public law section
    (B) in paragraph (2)(D), by inserting after “including new biological agents” the following: “and new clinical interventions to improve the health of those with muscular dystrophy”.

24 of 24 references resolved to an enrolled provision

Editorial Notes

References in Text

Section 6 of the MD–CARE Act, referred to in subsec. (a)(2), is section 6 of Pub. L. 107–84, which was formerly set out as a note under section 247b–18 of this title and does not relate to establishment of a coordinating committee. However, subsec. (d) of this section contains provisions relating to the establishment of the Muscular Dystrophy Coordinating Committee.

Prior Provisions

A prior section 283g, act July 1, 1944, ch. 373, title IV, § 404E, as added Pub. L. 103–43, title II, § 209, , 107 Stat. 149, related to Office of Alternative Medicine, prior to repeal by Pub. L. 105–277, div. A, § 101(f) [title VI, § 601(1)], , 112 Stat. 2681–337, 2681–387.

Amendments2007–2014 · 3 rounds

2014

Subsec. (a)(1). Pub. L. 113–166, § 2(1), substituted “Musculoskeletal” for “Muscoskeletal” and inserted “Becker, congenital muscular dystrophy, limb-girdle muscular dystrophy,” after “Duchenne,”.

Subsec. (b)(2). Pub. L. 113–166, § 2(2)(A), substituted “cardiac and pulmonary function, and pharmacological” for “genetics, pharmacological”.

Subsec. (b)(3). Pub. L. 113–166, § 2(2)(B), inserted “and sharing of data” after “regular communication”.

Subsec. (d)(2). Pub. L. 113–166, § 2(3)(A)(i), substituted “18” for “15” in introductory provisions.

Subsec. (d)(2)(A). Pub. L. 113–166, § 2(3)(A)(ii), substituted “, the Food and Drug Administration, and the Administration for Community Living” for “and the Food and Drug Administration” and “including the Department of Education and the Social Security Administration” for “such as the Department of Education” and inserted “and adults” after “children”.

Subsec. (d)(4)(B). Pub. L. 113–166, § 2(3)(B), inserted “, but shall meet no fewer than two times per calendar year” before period at end.

Subsec. (e)(1). Pub. L. 113–166, § 2(4)(A)(i), substituted “through the agencies represented on the Coordinating Committee pursuant to subsection (d)(2)(A)” for “through the national research institutes” in introductory provisions.

Subsec. (e)(1)(A). Pub. L. 113–166, § 2(4)(A)(ii), inserted “public services,” after “psychosocial,” and “, studies to demonstrate the cost-effectiveness of providing independent living resources and support to patients with various forms of muscular dystrophy, and studies to determine optimal clinical care interventions for adults with various forms of muscular dystrophy” after “including studies of the impact of such diseases in rural and underserved communities”.

Subsec. (e)(2)(D). Pub. L. 113–166, § 2(4)(B), inserted “and new clinical interventions to improve the health of those with muscular dystrophy” after “including new biological agents”.

2008

Subsec. (a)(1). Pub. L. 110–361, § 2(b)(1), inserted “the National Heart, Lung, and Blood Institute,” after “the Eunice Kennedy Shriver National Institute of Child Health and Human Development,”.

Subsec. (b)(1). Pub. L. 110–361, § 2(b)(2), inserted at end “Such centers of excellence shall be known as the ‘Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers’.”

Subsec. (f). Pub. L. 110–361, § 2(a), redesignated subsec. (g) as (f) and struck out former subsec. (f) which related to reports.

Subsec. (g). Pub. L. 110–361, § 2(a), (b)(3), added subsec. (g) and redesignated former subsec. (g) as (f).

2007

Pub. L. 109–482, § 104(b)(1)(A)(ii), which directed amendment of subsec. (b) by striking subsec. (f) and redesignating subsec. (g) as (f), could not literally be executed and was not executed in view of amendments by Pub. L. 110–361. See 2008 Amendment notes above.

Subsec. (a)(1). Pub. L. 110–154 substituted “Eunice Kennedy Shriver National Institute of Child Health and Human Development” for “National Institute of Child Health and Human Development”.

Subsec. (b)(3). Pub. L. 109–482, § 104(b)(1)(A)(i), amended heading and text of par. (3) generally. Text read as follows: “The Director of NIH—

“(A) shall, as appropriate, provide for the coordination of information among centers under paragraph (1) and ensure regular communication between such centers; and

“(B) shall require the periodic preparation of reports on the activities of the centers and the submission of the reports to the Director.”

Subsec. (h). Pub. L. 109–482, § 103(b)(4), struck out heading and text of subsec. (h). Text read as follows: “For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2002 through 2006. The authorization of appropriations established in the preceding sentence is in addition to any other authorization of appropriations that is available for conducting or supporting through the National Institutes of Health research and other activities with respect to muscular dystrophy.”

Statutory Notes and Related Subsidiaries

Effective Date of 2007 Amendment

Amendment by Pub. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109–482, set out as a note under section 281 of this title.

Credits

1944–2014 · 5 acts
  1. 1944July 1, 1944, ch. 373, title IV, § 404E, as added Pub. L. 107–84, § 3, , 115 Stat. 824
  2. 2007amended Pub. L. 109–482, title I, §§ 103(b)(4), 104(b)(1)(A), , 120 Stat. 3687, 3692
  3. 2007Pub. L. 110–154, § 1(b)(3), , 121 Stat. 1827
  4. 2008Pub. L. 110–361, § 2, , 122 Stat. 4010
  5. 2014Pub. L. 113–166, § 2, , 128 Stat. 1879.
Show as published

(July 1, 1944, ch. 373, title IV, § 404E, as added Pub. L. 107–84, § 3, , 115 Stat. 824; amended Pub. L. 109–482, title I, §§ 103(b)(4), 104(b)(1)(A), , 120 Stat. 3687, 3692; Pub. L. 110–154, § 1(b)(3), , 121 Stat. 1827; Pub. L. 110–361, § 2, , 122 Stat. 4010; Pub. L. 113–166, § 2, , 128 Stat. 1879.)

Parsed from the official OLRC USLM XML in data/usc_all/usc42.xml · release point 119-108 · OLRC build 2026-09-09

USLM identifier /us/usc/t42/s283g